Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing Exercise and Medication Timing in Metabolic Syndrome
NCT04477590Unknown
- Sponsor
- Universidad de Castilla-La Mancha
- Start
- Jun 2022
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Randomised, double-blind trial (3 arms), sponsored by Universidad de Castilla-La Mancha. Primary endpoints: Insulin sensitivity assessed using intravenous glucose tolerance test at 12 months, Post-prandial lipemia assessed by an oral fat tolerance test at 12 months and 2 more. Status: unknown.
Beyond the preview
Go deeper on NCT04477590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04477590.